[{"id":"fe141ae7-4238-43b1-a6a8-019252bc4d9e","acronym":"KEYNOTE F92","url":"https://clinicaltrials.gov/study/NCT05597839","created_at":"2022-10-28T13:56:59.300Z","updated_at":"2025-02-25T16:18:16.558Z","phase":"Phase 1/2","brief_title":"Study of DF9001 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05597839 - KEYNOTE F92","lead_sponsor":"Dragonfly Therapeutics","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" RET mutation • RAS wild-type","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • DF9001"],"overall_status":"Recruiting","enrollment":" Enrollment 242","initiation":"Initiation: 11/15/2022","start_date":" 11/15/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2024-05-15"}]